Network of Excellence for the development of advanced therapies for the treatment of myocardial infarction based on regenerative medicine and 3D printing


Detalles del proyecto

Abbreviation: Cardiopatch

Start date: 2020-09-01End date: 2023-04-30

Budget: 1.419.000 €

Centre bugdet: 200.000 €

Funding: €150,000 (Interreg Sudoe Programme)


The SUDOE regions share the common challenge of tackling the burden posed by chronic diseases, including cardiovascular disease (CVD), Europe's leading cause of mortality and morbidity. Myocardial infarction (MI) is the leading cause of death from CVD. Addressing this challenge requires advances in the development of new solutions. CARDIOPATCH will be the first Network of Excellence in the SUDOE region that will:

1) Develop an innovative model of advanced therapy for MI treatment: a regenerative cell therapy based on three products – the CARDIOPATCH cell regeneration patch, the 3D system for its production and transport, and the 3D device for its non-invasive implantation in the heart.

2) Provide regions with tools to explore the synergies between their health and 3D printing sectors in order to redesign smarter health specialisation strategies and develop more up-to-date public policies in terms of MI treatment.

  • University of Navarra (UN)
  • Foundation for Applied Medical Research (FIMA)
  • Research Institute Foundation of Hospital de la Santa Creu i Sant Pau (FIRHSCSP)
  • Institute of Experimental Biology and Technology (IBET)
  • GUK Komunikazio Aholkularitza (GUK)
  • Toulouse University Hospital (CHUT)
  • University of Montpellier (UM) - Max Mousseron Institute of Biomolecules (IBMM)
  • GenIbet Biopharmaceuticals S. A. (GENIBET)
  • Leartiker S. Coop. (LEARTIKER
Activities carried out by Leartiker
  • Development of the 3D system for the culture and transport of the cellularized Cardiopatch patch. Working with clinical partners (UN, CHUT, FIRHSCSP), the requirements will be defined and the developed system will be designed, manufactured and tested.
  • Design, development and manufacture of a tool for the minimally invasive implantation of the patch. The goal is to avoid thoracotomy as a method of access to the affected region.
  • In addition, it will be involved in the efforts to characterise the developed membranes, as well as in the management of the transfer and use of the developed products.

This website uses its own and third-party cookies in order to offer you the best possible user experience.

Before continuing, you must decide what to do with these cookies. You can accept all or save the selection you make.


We use the technical cookies necessary for the operation of the website and we save your preferences for cookie settings and chosen language.


We use third-party sites to analyze browsing and to display embedded information (YouTube and Flickr). Activate the desired options.

Not accepting third-party cookies will mean that we do not show you certain content. Although we will show you a link to access them.

For more information see: Privacy policy